ZEVRA THERAPEUTICS, INC.
About ZEVRA THERAPEUTICS, INC.
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2015
- $0
- Net income
- $83.2M
- Total assets
- $284.7M
- Market cap
- $627.2M
- Operating margin
- -59.1%
- Net margin
- 78.2%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $106.5M
- Operating expenses
- $169.4M
- Operating income
- -$62.9M
- Income tax
- $3.4M
- Net income
- $83.2M
- EPS (basic)
- $1.40
- EPS (diluted)
- $1.35
Balance sheet
- Total assets
- $284.7M
- Current assets
- $223.0M
- Total liabilities
- $130.1M
- Current liabilities
- $39.3M
- Shareholders’ equity
- $154.7M
Cash flow
- Operating cash flow
- -$1.6M
- Investing cash flow
- $18.1M
- Financing cash flow
- $12.1M
- Net cash flow
- $28.6M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $627.2M
- P/E ratio
- 9.0
- EPS (diluted)
- $1.35
- Shares outstanding
- 51.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 16, 2015
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $83.2M in FY2015.
- Revenue grew 288% from FY2023 to FY2025.
- Trading 5% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 9.0.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review ZEVRA THERAPEUTICS, INC..
Write a review
News about ZEVRA THERAPEUTICS, INC.
News & sentiment via Polygon.io
